Answer
Based on population pharmacokinetic analysis, belantamab mafodotin (ADC) has a geometric mean elimination half-life of 13 days initially (geometric CV 26%) and 17 days at steady state (geometric CV 31%).
Sources for this answer
- Blenrep 100mg & 70 mg powder for concentrate for solution for infusionGlaxoSmithKline UK · emc · SmPC §5.2 Pharmacokinetic properties · Version 2Document updated
Sources checked